Eagle Pharmaceuticals (EGRX): $0.23 million was the positive money flow into the stock on Friday and the up/down ratio of ticks was also in favor of the bulls at 1.2. The value of trades done on upticks was $1.4 million, whereas, trades done on downticks were valued at $1.17 million. Money flows are calculated as the dollar value of composite uptick trades minus the dollar value of downtick trades. large traders, also sometimes called as the smart money, block traded $0 million worth stocks on upticks, which is a bullish indication. The money flow in block trades was $0 million. Eagle Pharmaceuticals (EGRX) fell $0.07 traded at $58.95, a change of -0.12% over the previous day. The stock is -2.13% for the week.
The company Insiders own 18.8% of Eagle Pharmaceuticals shares according to the proxy statements. During last six month period, the net percent change held by insiders has seen a change of -2.2%.
In a related news, Tarriff Scott, director officer (President and CEO) of Eagle Pharmaceuticals, Inc., unloaded 30,765 shares at an average price of $40.63 on April 1, 2016. The total amount of the transaction was worth $1,249,982, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Eagle Pharmaceuticals (NASDAQ:EGRX): The stock opened at $59.32 and touched an intraday high of $60.43 on Friday. During the day, the stock corrected to an intraday low of $57.61, however, the bulls stepped in and pushed the price higher to close in the green at $60.34 with a gain of 2.24% for the day. The total traded volume for the day was 372,076. The stock had closed at $59.02 in the previous trading session.
On a relative basis, the stock has outperformed the S&P 500 by 21.96% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.18% in the last 1 week, and is up 21.8% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
Eagle Pharmaceuticals, Inc. (Eagle Pharmaceuticals) is a specialty pharmaceutical company. The Company focused on developing and commercializing injectable products. It develops products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially injectable products. Its two most advanced product candidates are EP-3101 (bendamustine RTD), an intravenous version of the chemotherapeutic agent that is marketed by Teva under the brand name Treanda, and Ryanodex (dantrolene for MH), and an intravenous version of an approved treatment for malignant hyperthermia. Its products include EP-3101, EP-3102, Ryanodex, EP-4104, EP-6101, EP-5101, EP-1101 and EP-2101. Teva markets its bendamustine product under the trade name Treanda.